Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth

Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR of the activating ligands testosterone (T) and dihydrotestosterone (DHT) by limiting their biosynthesis or blocking AR b...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Nyquist, Michael D., Ang, Lisa S., Corella, Alexandra, Coleman, Ilsa M., Meers, Michael P., Christiani, Anthony J., Pierce, Cordell, Janssens, Derek H., Meade, Hannah E., Bose, Arnab, Brady, Lauren, Howard, Timothy, De Sarkar, Navonil, Frank, Sander B., Dumpit, Ruth F., Dalton, James T., Corey, Eva, Plymate, Stephen R., Haffner, Michael C., Mostaghel, Elahe A., Nelson, Peter S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2021
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121509/
https://ncbi.nlm.nih.gov/pubmed/33998604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI146777
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi